Identification of a Cytochrome P450 2C9-Derived Endothelium-Derived Hyperpolarizing Factor in Essential Hypertensive Patients

Journal of the American College of Cardiology

Volumn 48, Issue 3, 2006, Pages 508-515

  Taddei, Stefano ^a   Versari, Daniele ^a   Cipriano, Alessandro ^a   Ghiadoni, Lorenzo ^a   Galetta, Fabio ^a   Franzoni, Ferdinando ^a   Magagna, Armando ^a   Virdis, Agostino ^a   Salvetti, Antonio ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ANTIOXIDANT; ASCORBIC ACID; BRADYKININ; CYTOCHROME P450 2C9; CYTOCHROME P450 INHIBITOR; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; N(G) METHYLARGININE; NITROPRUSSIDE SODIUM; PROSTAGLANDIN SYNTHASE INHIBITOR; SULFAPHENAZOLE;

ADULT; AGONIST; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; ESSENTIAL HYPERTENSION; FEMALE; FOREARM BLOOD FLOW; HUMAN; MALE; MICROCIRCULATION; PERIPHERAL CIRCULATION; PLETHYSMOGRAPHY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; VASODILATATION;

ACETYLCHOLINE; ADULT; ARYL HYDROCARBON HYDROXYLASES; ASCORBIC ACID; BIOLOGICAL FACTORS; BRADYKININ; CASE-CONTROL STUDIES; DRUG COMBINATIONS; DRUG SYNERGISM; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; FEMALE; FOREARM; HUMANS; HYPERTENSION; MALE; MICROCIRCULATION; MIDDLE AGED; NITROPRUSSIDE; OMEGA-N-METHYLARGININE; REGIONAL BLOOD FLOW; SULFAPHENAZOLE; VASODILATION; VASODILATOR AGENTS;

EID: 33746192641     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2006.04.074     Document Type: Article

References (25)

1. Taddei S., and Salvetti A. Endothelial dysfunction in essential hypertension. clinical implications. J Hypertens 20 (2002) 1671-1674
2. Panza J.A., Quyyumi A.A., Brush Jr. J.E., and Epstein S.E. Abnormal endothelium dependent vascular relaxation in patients with essential hypertension. N Engl J Med 323 (1990) 22-27
3. Taddei S., Virdis A., Mattei P., and Salvetti A. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 21 (1993) 929-933
4. Panza J.A., García C.E., Kilcoyne C.M., Quyyumi A., and Cannon III R.O. Impaired endothelium-dependent vasodilation in patients with essential hypertension. Evidence that nitric oxide abnormality is not localised to a single signal transduction pathway. Circulation 91 (1995) 1732-1738
5. Taddei S., Virdis A., Ghiadoni L., Magagna A., and Salvetti A. Vitamin C improves endothelium-dependent vasodilatation by restoring nitric oxide activity in essential hypertension. Circulation 97 (1998) 2222-2229
6. Taddei S., Virdis A., Taddei S., et al. Vasodilation to bradykinin is mediated by an ouabain-sensitive pathway as a compensatory mechanism for impaired NO availability in essential hypertensive patients. Circulation 100 (1999) 1400-1405
7. Fleming I. Cytochrome P450 epoxygenases as EDHF synthase(s). Pharmacol Res 49 (2004) 525-533
8. Komori K., and Vanhoutte P.M. Endothelium-derived hyperpolarizing factor. Blood Vessels 27 (1990) 238-245
9. Campbell W.B., Gebremedhin D., Pratt P.F., and Harder D.R. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 78 (1996) 415-423
10. + is an endothelium-derived hyperpolarizing factor in rat arteries. Nature 396 (1998) 269-272
11. Fisslthaler B., Popp R., Kiss L., et al. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 401 (1999) 493-497
12. Ca channels. Circulation 107 (2003) 769-776
13. Halcox J.P., Narayanan S., Cramer-Joyce L., Mincemoyer R., and Quyyumi A.A. Characterization of endothelium-derived hyperpolarizing factor in the human forearm microcirculation. Am J Physiol Heart Circ Physiol 208 (2001) H2470-H2477
14. Fleming I., Michaelis U.R., Bredenkotter D., et al. Endothelium-derived hyperpolarizing factor synthase (cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ Res 88 (2001) 44-51
15. Fichtlscherer S., Dimmeler S., Breuer S., Busse R., Zeiher A.M., and Fleming I. Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease. Circulation 109 (2004) 178-183
16. Virdis A., Taddei S., Ghiadoni L., et al. Mechanisms responsible for endothelial dysfunction induced by fasting hyperhomocyst(e)inemia in normotensive subjects and essential hypertensive patients. J Am Coll Cardiol 38 (2001) 1106-1115
17. Frei B., England L., and Ames B.N. Ascorbate is an outstanding antioxidant in human blood plasma. Proc Natl Acad Sci U S A 86 (1989) 6377-6381
18. Coats P., Johnston F., MacDonald J., McMurray J.J.V., and Hillier C. Endothelium-derived hyperpolarizing factor. Identification and mechanisms of action in human subcutaneous resistance arteries. Circulation 103 (2001) 1702-1708
19. Bolz S.B., Fisslthaler B., Pieperhoff S., et al. Antisense oligonucleotides against cytochrome P450 2C8 attenuate EDHF-mediated Ca2+ changes and dilation in isolated resistance arteries. FASEB J 14 (2000) 255-260
20. Hillig T., Krustrup P., Fleming I., Osada T., Saltin B., and Hellsten Y. Cytochrome P450 2C9 plays an important role in the regulation of exercise-induced skeletal muscle blood flow and oxygen uptake in humans. J Physiol 546 (2003) 307-314
21. Bauersachs J., Popp R., Hecker M., Sauer E., Fleming I., and Busse R. Nitric oxide attenuates the release of endothelium-derived hyperpolarizing factor. Circulation 94 (1996) 3341-3347
22. Feletou M., and Vanhoutte P.M. Activation of vascular smooth muscle K+ channels by endothelium-derived factors. In: Archer S.L., and Rusch N.J. (Eds). Potassium Channels in Cardiovascular Biology (2001), Kluwer Academic/Plenum, New York, NY 691-712
23. Taddei S., Virdis A., Mattei P., Natali A., Ferrannini E., and Salvetti A. Effect of insulin on acetylcholine-induced vasodilation in normotensive subjects and patients with essential hypertension. Circulation 92 (1995) 2911-2918
24. Vita J.A., Treasure C.B., Nabel E.G., et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 81 (1990) 491-497
25. Benjamin E.J., Larson M.G., Keyes M.J., et al. Clinical correlates and heritability of flow-mediated dilation in the community. the Framingham Heart study. Circulation 109 (2004) 613-619